ResMed Inc.

ticker: RMD step: 01 generated: 2026-05-12 source: quick-research

ResMed Inc. (RMD) — Business Overview

Business Description

ResMed Inc. is a global medical device and software company specializing in cloud-connected devices for sleep apnea, COPD, and other respiratory conditions, as well as out-of-hospital software platforms for home care and residential care providers. Founded in 1989 and headquartered in San Diego, California, ResMed holds approximately 62% of the global CPAP market by device rankings and operates one of the most comprehensive sleep health ecosystems, with 28 million patients monitored through its AirView platform and over 26 million cloud-connected devices across 140 countries.

Revenue Model

ResMed generates revenue through two streams: (1) device and consumables sales — CPAP/APAP/bilevel machines plus masks and accessories (~88% of revenue); and (2) Residential Care Software SaaS subscriptions (~12% of revenue). Recurring revenue is driven by masks and accessories (replaced every 3–6 months) and software subscription contracts with home healthcare providers and hospitals. Cloud-connected devices feed data into AirView, which deepens customer lock-in and enables compliance reporting required by payers for reimbursement continuation.

Products & Services

• AirSense / AirCurve — flagship CPAP/APAP/bilevel devices with cloud connectivity and built-in sleep scoring algorithms
• Masks & Accessories — nasal pillows, full-face masks, and accessories; highest-margin consumable line
• AirView — cloud platform for providers to remotely monitor patient therapy adherence across 28M+ patients
• myAir — patient-facing app with 8.3M+ registered users for self-monitoring and engagement
• Brightree — home health and hospice workflow/billing software for ~4,400 home medical equipment providers
• MatrixCare — senior living and long-term care management software platform
• HME/Home Health — revenue cycle management and clinical documentation for home care operators

Customer Base & Go-to-Market

ResMed sells devices primarily through distributors (home medical equipment dealers, hospital supply chains) and directly to large health systems. Software products (Brightree, MatrixCare) are sold via direct SaaS contracts to home health agencies, hospices, and senior living operators. The U.S. represents ~64% of revenue; rest-of-world accounts for ~36%. No single customer represents a material concentration. Payer reimbursement requirements (Medicare/Medicaid mandating 90-day adherence compliance) create structural demand for ResMed's monitoring ecosystem.

Competitive Position

ResMed is the dominant global player in sleep therapy devices with ~62% market share, far ahead of competitor Philips (which exited the US market in 2021 due to device recalls and is now returning) and smaller players like Fisher & Paykel. The company's competitive moat rests on: 8,200+ patents limiting device replication, a 20-billion-night proprietary sleep dataset enabling superior algorithms, AirView's deep integration into provider workflows creating high switching costs, and masks/accessories consumable pull-through from a large installed device base.

Key Facts

• Founded: 1989
• Headquarters: San Diego, California
• Employees: ~10,000
• Exchange: NYSE
• Sector / Industry: Health Care / Medical Devices
• Market Cap: ~$28–32B

ticker: RMD step: 04 generated: 2026-05-12 source: quick-research

ResMed Inc. (RMD) — Financial Snapshot

Note: ResMed's fiscal year ends June 30. FY2024 = July 2023 – June 2024.

Income Statement Summary

FY2025 revenue: $5.15B (+9.8%); FY2025 EPS estimated ~$8.00+ based on Q-by-Q beat trajectory.

Cash Flow & Balance Sheet (FY2024)

Key Ratios (approximate)

• P/E: ~25–30x | EV/EBITDA: ~22x | FCF Yield: ~4%
• Revenue Growth (FY2024): +11% | FCF Margin: ~27%
• Net Debt / EBITDA: ~1x (conservative leverage)

Growth Profile

ResMed has compounded revenue at ~14% annually over the 2022–2024 period, driven by share gains following Philips' 2021 recall-related U.S. exit (a windfall that is now normalizing) and organic demand growth in an underpenetrated sleep apnea market (only ~15–20% of diagnosed patients treated). Gross margins have expanded steadily from ~54% to ~57% as device mix improves and software revenue scales. Free cash flow conversion is strong at ~27% of revenue, enabling consistent share buybacks and debt reduction.

Forward Estimates

• FY2026 (ending June 2026) revenue consensus: ~$5.4–5.6B (+5–8% growth)
• FY2026 adjusted EPS: ~$9.00–9.50 (consensus Buy; analyst fair value target ~$256)
• Management revised FY2026 respiratory segment growth to mid-single digits (from upper mid-single digits) reflecting Philips re-entry headwinds; software remains a faster-growing segment

ticker: RMD step: 12 generated: 2026-05-12 source: quick-research

ResMed Inc. (RMD) — Investment Catalysts & Risks

Bull Case Drivers

1. GLP-1 Narrative Reversal — ResMed's own claims data across 1.95 million patients shows that GLP-1 drugs (Ozempic, Wegovy) are net positive for the sleep therapy business: patients prescribed both a GLP-1 and a CPAP device are 10–11% more likely to start CPAP therapy and stay on it longer. The initial market concern that obesity drugs would eliminate sleep apnea demand appears empirically wrong — weight loss reduces apnea severity but many structural/anatomical cases persist, and drug-motivated weight loss patients are more engaged with their health overall. This narrative reset, if sustained, is a meaningful re-rating catalyst.

2. Massive Underpenetrated Market — Approximately 936 million people globally have sleep apnea; only ~15–20% are currently diagnosed and treated. The global CPAP market is valued at ~$7.1B in 2025 and growing. As awareness, telemedicine adoption, and at-home sleep testing expand the diagnosed pool, ResMed — with 62% market share — is well positioned to capture incremental volume without needing to gain share. Emerging markets (Asia Pacific, Latin America) represent a long runway for device and software expansion.

3. Software Recurring Revenue Flywheel — Brightree and MatrixCare collectively serve over 4,400 home health agencies and senior living operators. As these platforms grow ARR and expand into adjacent workflows (telehealth, AI-assisted documentation), the 12% software revenue share should scale — and software revenue commands higher gross margins (~70–75%) than devices, structurally lifting overall profitability. ResMed's 2030 strategy targets meaningful software mix expansion.

Bear Case Risks

1. GLP-1 Long-Term Structural Threat — Despite near-term data showing complementary use, the 10–15 year bull case for GLP-1 drugs (semaglutide, tirzepatide) is mass weight loss across the population. Since 70–90% of obstructive sleep apnea cases are obesity-driven, broad GLP-1 adoption could structurally reduce OSA prevalence. If 30–50% of CPAP users eventually resolve their apnea through weight loss, the replacement and new-patient market will compress. This is a slow-moving but existential risk that the market is still pricing in.

2. Philips Re-Entry Competitive Pressure — Philips exited the U.S. sleep therapy market in 2021 after massive recall issues (foam degradation in older devices), gifting ResMed unprecedented market share gains. Philips is now returning to the U.S. market with new devices. Even a partial recovery to Philips' prior ~30% U.S. share could meaningfully pressure ResMed's device volumes and pricing. Management has already revised FY2026 respiratory segment growth guidance downward citing competitive headwinds.

3. Valuation Richness and Earnings Miss Risk — With RMD trading at ~25–30x earnings even after being down ~22% in 2026, the stock embeds a premium growth narrative. Any deceleration in device volumes (from Philips competition, GLP-1 adoption, or macro headwinds in home health reimbursement) could trigger a multiple de-rating. Payer policy changes (CMS reimbursement cuts for durable medical equipment) represent a recurring policy risk that could impair home health channel demand.

Upcoming Events

• Q4 FY2026 Earnings (August 2026): Full year FY2026 results — key for validating management's revised mid-single-digit respiratory growth guidance
• GLP-1 longitudinal data updates: ResMed tracking ~2M patient claims; each quarterly data release will either confirm or challenge the "GLP-1 helps CPAP" thesis
• Philips market re-entry: Ongoing competitive dynamics in the U.S. CPAP market as Philips ramps distribution

Analyst Sentiment

Analyst consensus is constructive: ~63% Buy/Strong Buy, ~36% Hold, <2% Sell. Consensus price target clusters around $250–$260 vs. current ~$208 stock price (implying ~20–25% upside). Key debate is GLP-1 structural risk vs. near-term earnings execution. Most bulls see the 22% YTD 2026 drawdown as an overreaction to GLP-1 fears given actual patient data.

Research Date

Generated: 2026-05-12